More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat early-stage bladder cancer.
May 29, 2025
0
20
A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results of an international Phase I/II clinical trial led by researchers at Washington ...
May 30, 2025
0
53
A team of scientists at the Research Institute of the McGill University Health Center (The Institute) has made a landmark discovery that sheds light on how the immune system protects the gut during infection. By studying ...
May 29, 2025
0
56
Beloved Australian actor, Magda Szubanski, has revealed she's been diagnosed with a "very rare, very aggressive, very serious" blood cancer called mantle cell lymphoma.
May 31, 2025
0
0
Recent research points to the potential utility of a familiar sounding foe–herpes virus–in the fight against cancer.
May 28, 2025
0
88
Researchers from the Centenary Institute have uncovered a reason why some people with hemophilia A develop resistance to their critical treatment, paving the way for the development of more effective therapies. The study ...
May 28, 2025
0
0
A new targeted cancer drug, DB-1310, is showing early signs of effectiveness in patients with advanced solid tumors that have not responded to standard treatments, particularly those with EGFR-mutant non-small cell lung cancer ...
May 30, 2025
0
0
Patients with systemic sclerosis or Sjögren's syndrome suffer from various inflammatory reactions triggered by the body's own immune system. A team of researchers has investigated the role of certain immune cells in the ...
May 27, 2025
0
0
B-cell acute lymphoblastic leukemia (B-ALL) is the most common cancer in children, accounting for around 85% of pediatric leukemia cases. According to REDECAN, more than 400 new cases are estimated to be diagnosed in Spain ...
May 27, 2025
0
0
In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus pembrolizumab resulted in durable responses with improved progression free survival compared to the ...
8 hours ago
0
0
